What the semaglutide trials actually established
Semaglutide is one of the best-studied drugs of the decade. Knowing which trial proved what — and what none of them proved — is how you read past the marketing.
The pivotal semaglutide evidence comes from four trial programs. STEP tested injectable semaglutide 2.4 mg for weight management (about 15% average loss in STEP-1). SUSTAIN tested it for type 2 diabetes. PIONEER tested oral semaglutide (Rybelsus) for diabetes. SELECT showed a 20% reduction in major cardiovascular events in people with obesity and established CV disease. Critically, all of this evidence is for FDA-approved products, not compounded formulations.
- STEP: The STEP program tested injectable semaglutide 2.4 mg weekly for chronic weight management.
- SUSTAIN: The SUSTAIN program established injectable semaglutide (Ozempic) for type 2 diabetes, showing meaningful reductions in HbA1c and body weight across a .
- PIONEER: The PIONEER program tested oral semaglutide (Rybelsus) for type 2 diabetes, establishing that semaglutide could work as a daily tablet — but only with.
- SELECT: SELECT was a landmark: in adults with established cardiovascular disease and obesity or overweight but without diabetes, injectable semaglutide 2.4 mg.
- Why brand evidence doesn't transfer to compounded: Every trial above tested an FDA-approved product manufactured to consistent specifications.
STEP: the weight-management evidence
The STEP program tested injectable semaglutide 2.4 mg weekly for chronic weight management. In STEP-1, adults with obesity or overweight without diabetes lost an average of about 14.9 percent of body weight over 68 weeks, versus 2.4 percent on placebo — with roughly a third losing 20 percent or more. Later STEP trials extended the findings to different populations and confirmed durability while treatment continued.
STEP is the evidentiary foundation for Wegovy's weight-management approval. It is also the number the whole compounded-semaglutide market implicitly borrows: when a program says “semaglutide produces about 15 percent weight loss,” that figure comes from STEP, which tested the approved injectable — not the compounded or sublingual product being sold.
| Program | Product tested | What it established | Approval it supports |
|---|---|---|---|
| STEP | Injectable sema 2.4 mg | ~15% weight loss | Wegovy (weight mgmt) |
| SUSTAIN | Injectable sema (Ozempic) | HbA1c + weight reduction | Ozempic (diabetes) |
| PIONEER | Oral sema + SNAC | Oral semaglutide viable | Rybelsus (diabetes) |
| SELECT | Injectable sema 2.4 mg | ~20% fewer CV events | Wegovy (CV risk) |
SUSTAIN: the diabetes evidence
The SUSTAIN program established injectable semaglutide (Ozempic) for type 2 diabetes, showing meaningful reductions in HbA1c and body weight across a range of comparators and add-on regimens. It is why Ozempic is a mainstay of diabetes care and why plans cover it under diabetes criteria.
SUSTAIN matters for cost discussions because it explains the coverage split: a drug with robust diabetes evidence gets covered for diabetes, while the same molecule for weight loss depends on separate weight-management approval and separate, often-excluded, benefit design. The evidence base is indication-specific, and so is the insurance.
PIONEER: the oral evidence
The PIONEER program tested oral semaglutide (Rybelsus) for type 2 diabetes, establishing that semaglutide could work as a daily tablet — but only with the SNAC absorption enhancer and strict dosing conditions. PIONEER is the reason Rybelsus exists and the reason oral semaglutide is possible at all.
It is also the trial program most often misappropriated. PIONEER validated a specific oral formulation with a specific absorption technology. It did not validate compounded sublingual tablets, which use neither Rybelsus's formulation nor its route. Citing PIONEER to support a compounded ODT product is a category error, as our ODT evidence guide explains.
SELECT: the cardiovascular evidence
SELECT was a landmark: in adults with established cardiovascular disease and obesity or overweight but without diabetes, injectable semaglutide 2.4 mg reduced major adverse cardiovascular events — heart attack, stroke, cardiovascular death — by about 20 percent versus placebo. This moved semaglutide from a metabolic drug to a cardiovascular one.
SELECT underpins Wegovy's cardiovascular indication and, practically, opens a coverage pathway: a patient with established CV disease may qualify for coverage on cardiovascular grounds even where a plan excludes weight-loss drugs. The evidence created not just a clinical benefit but an access route.
Why brand evidence doesn't transfer to compounded
Every trial above tested an FDA-approved product manufactured to consistent specifications. Compounded semaglutide is prepared by pharmacies without premarket FDA review for safety, effectiveness, or quality, and its potency, purity, and — for non-injectable routes — absorption are not established by these trials.
This is the single most important reading-skill for semaglutide marketing. “Clinically proven,” “15 percent weight loss,” “backed by research” — these claims trace to trials of the approved products. A compounded injectable may plausibly behave similarly if it truly contains the same active ingredient at the labeled dose, but that is an inference, not a tested result. For sublingual and oral compounded products using different routes, even the inference fails.
What the evidence lets you conclude
You can conclude a great deal: injectable semaglutide produces substantial, durable weight loss while taken; it improves glycemic control; it reduces cardiovascular events in a high-risk population; and oral semaglutide works for diabetes with the right formulation. These are strong, replicated findings.
You cannot conclude that any compounded product shares these results by virtue of containing semaglutide. The evidence attaches to specific products at specific doses by specific routes. When a program invites you to transfer the trial numbers to its compounded formulation, the correct response is to ask what evidence exists for that specific product — and to notice when the answer is none.
One further distinction sharpens the point. Trials report both relative and absolute effects, and marketing tends to quote whichever sounds larger. SELECT's roughly 20 percent reduction in cardiovascular events is a relative figure; the absolute reduction in event rate over the trial was a few percentage points, which is still clinically meaningful but a different number. When a program cites a trial statistic, it is worth asking whether the figure is a relative or absolute effect, over what timeframe, and in which population, because those qualifiers change what the number means for any individual reader.
Frequently asked questions
Does compounded semaglutide have the same evidence as Wegovy?
No. The STEP, SUSTAIN, PIONEER, and SELECT trials all tested FDA-approved products. Compounded semaglutide has not undergone that testing; brand results are an inference for compounded injectables and don't apply at all to sublingual or oral compounded formulations.
Which trial is the weight-loss trial?
STEP is the weight-management program (about 15% average loss in STEP-1 with injectable semaglutide 2.4 mg). SELECT added the cardiovascular benefit. SUSTAIN and PIONEER are diabetes programs.
Can I use PIONEER to judge a sublingual ODT product?
No. PIONEER tested Rybelsus, an oral tablet with the SNAC absorption enhancer taken on an empty stomach. A compounded sublingual ODT uses a different route and formulation, so PIONEER's results don't transfer.